Abstract
Objective: To systematically characterize the impurity profile in Daptomycin raw material by 2 Dimensional LC/MSn.
Methods: The target impurity was separated by first Dimensional HPLC and enriched by a 500μl loop, then desalted using the on-line second Dimensional HPLC and analyzed by MS detector in positive mode. Their structures were characterized based on the degradation mechanism and mass fragmentation regularity of the cyclic lipopeptide, as well as the molecular thermodynamic calculation.
Results: A total of 12 impurities were characterized in the raw material, including 6 degradation products; 8 impurities are reported for the first time. The mass fragmentation regularities of 2 β-isomers of Asp residue were summarized.
Conclusion: The structures of impurities in Daptomycin raw material, especially for β-isomer impurities, could be rapidly identified by on-line 2 Dimensional LC/MSn method together with the molecular thermodynamic calculation.
Keywords: Antibiotics, daptomycin, impurity profile, lipopeptide, LC/MSn, impurities.
Graphical Abstract
[1]
Johnson, A. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria. Future Microbiol., 2006, 1(3), 255-265.
[http://dx.doi.org/10.2217/17460913.1.3.255] [PMID: 17661638]
[http://dx.doi.org/10.2217/17460913.1.3.255] [PMID: 17661638]
[2]
Heidary, M.; Khosravi, A.D.; Khoshnood, S.; Nasiri, M.J.; Soleimani, S.; Goudarzi, M. Daptomycin. J. Antimicrob. Chemother., 2018, 73(1), 1-11.
[http://dx.doi.org/10.1093/jac/dkx349] [PMID: 29059358]
[http://dx.doi.org/10.1093/jac/dkx349] [PMID: 29059358]
[3]
Kosmidis, C.; Levine, D.P. Daptomycin: pharmacology and clinical use. Expert Opin. Pharmacother., 2010, 11(4), 615-625.
[http://dx.doi.org/10.1517/14656561003598893] [PMID: 20163272]
[http://dx.doi.org/10.1517/14656561003598893] [PMID: 20163272]
[4]
Sakoulas, G.; Golan, Y.; Lamp, K.C.; Friedrich, L.V.; Russo, R. Daptomycin in the treatment of bacteremia. Am. J. Med., 2007, 120(10)(Suppl. 1), S21-S27.
[http://dx.doi.org/10.1016/j.amjmed.2007.07.012] [PMID: 17904947]
[http://dx.doi.org/10.1016/j.amjmed.2007.07.012] [PMID: 17904947]
[5]
Schriever, C.A.; Fernández, C.; Rodvold, K.A.; Danziger, L.H. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am. J. Health Syst. Pharm., 2005, 62(11), 1145-1158.
[http://dx.doi.org/10.1093/ajhp/62.11.1145] [PMID: 15914875]
[http://dx.doi.org/10.1093/ajhp/62.11.1145] [PMID: 15914875]
[6]
Jeu, L.; Fung, H.B. Daptomycin: a cyclic lipopeptide antimicrobial agent. Clin. Ther., 2004, 26(11), 1728-1757.
[http://dx.doi.org/10.1016/j.clinthera.2004.11.014] [PMID: 15639687]
[http://dx.doi.org/10.1016/j.clinthera.2004.11.014] [PMID: 15639687]
[7]
Fenton, C.; Keating, G.M.; Curran, M.P. Daptomycin. Drugs, 2004, 64(4), 445-455.
[http://dx.doi.org/10.2165/00003495-200464040-00009] [PMID: 14969579]
[http://dx.doi.org/10.2165/00003495-200464040-00009] [PMID: 14969579]
[8]
Tedesco, K.L.; Rybak, M.J. Daptomycin. Pharmacotherapy, 2004, 24(1), 41-57.
[http://dx.doi.org/10.1592/phco.24.1.41.34802] [PMID: 14740787]
[http://dx.doi.org/10.1592/phco.24.1.41.34802] [PMID: 14740787]
[9]
Silverman, J.A.; Perlmutter, N.G.; Shapiro, H.M. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother., 2003, 47(8), 2538-2544.
[http://dx.doi.org/10.1128/AAC.47.8.2538-2544.2003] [PMID: 12878516]
[http://dx.doi.org/10.1128/AAC.47.8.2538-2544.2003] [PMID: 12878516]
[10]
Taylor, S.D.; Palmer, M. The action mechanism of daptomycin. Bioorg. Med. Chem., 2016, 24(24), 6253-6268.
[http://dx.doi.org/10.1016/j.bmc.2016.05.052] [PMID: 27288182]
[http://dx.doi.org/10.1016/j.bmc.2016.05.052] [PMID: 27288182]
[11]
Zhang, T.; Muraih, J.K.; MacCormick, B.; Silverman, J.; Palmer, M. Daptomycin forms cation- and size-selective pores in model membranes. Biochim. Biophys. Acta, 2014, 1838(10), 2425-2430.
[http://dx.doi.org/10.1016/j.bbamem.2014.05.014] [PMID: 24857935]
[http://dx.doi.org/10.1016/j.bbamem.2014.05.014] [PMID: 24857935]
[12]
Q3A(R2): Impurities in New Drug Substances, International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Geneva 2006.
http://www.ich.org
[13]
European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP)/Committee for Medicinal Products for Veterinary Use (CVMP) Guideline on setting specifications for related impurities in antibiotics, 2009.
[14]
Hu, C.Q. Current situation and the trend in impurity control of chemical drugs, Sinica. Chimica., 2010, 40, 679-687.
[http://dx.doi.org/10.1360/zb2010-40-6-679]
[http://dx.doi.org/10.1360/zb2010-40-6-679]
[15]
Hu, C.Q. Current situation and the trend in impurity profiling of chemical drugs. Zhongguo Xin Yao Zazhi, 2015, 24, 1727-1734.
[http://dx.doi.org/10.1016/S1872-2067(10)60128-3]
[http://dx.doi.org/10.1016/S1872-2067(10)60128-3]
[17]
Kirsch, L.E.; Molloy, R.M.; Debono, M.; Baker, P.; Farid, K.Z.; Khadiga, F. Kinetics of the aspartyl transpeptidation of daptomycin, a novel lipopeptide antibiotic. Pharm. Res., 1989, 6(5), 387-393.
[http://dx.doi.org/10.1023/A:1015927330908] [PMID: 2546142]
[http://dx.doi.org/10.1023/A:1015927330908] [PMID: 2546142]
[18]
Wang, W. From Natural Products to Drugs- Development of Daptomycin, World Notes on antibio 2009, 59-62.
[19]
Zhang, D.F.; Xia, X.; Su, Y. H.; Rao, M.; Sun, X. Q.; Ge, M. Characterization of impurities derived from Daptomycin in different pH, Zhong guo Kang sheng su Za zhi 2013, 760-764.
[20]
Thomas, K.; Lai, J. J.; Joseph, P. D.; Paul, L.; Maurizio, Z.; Auro, T. High purity lipopeptides: US 20070191280A1 2007.
[21]
Muangsiri, W.; Kirsch, L.E. The kinetics of the alkaline degradation of daptomycin. J. Pharm. Sci., 2001, 90(8), 1066-1075.
[http://dx.doi.org/10.1002/jps.1060] [PMID: 11536211]
[http://dx.doi.org/10.1002/jps.1060] [PMID: 11536211]
[22]
Gu, J.Q.; Nguyen, K.T.; Gandhi, C.; Rajgarhia, V.; Baltz, R.H.; Brian, P.; Chu, M. Structural characterization of daptomycin analogues A21978C1-3(d-Asn11) produced by a recombinant Streptomyces roseosporus strain. J. Nat. Prod., 2007, 70(2), 233-240.
[http://dx.doi.org/10.1021/np0605135] [PMID: 17284073]
[http://dx.doi.org/10.1021/np0605135] [PMID: 17284073]
[23]
Needham, S.R. Fast Efficient Separations in Drug Discovery-LC-MS Analysis Using Column Switching and Rapid Gradients. LCGC ASIA PACIFIC., 2002, 5, 18-21.
[24]
Zanchetti, G.; Floris, I.; Piccinotti, A.; Tameni, S.; Polettini, A. Rapid and robust confirmation and quantification of 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH) in urine by column switching LC-MS-MS analysis. J. Mass Spectrom., 2012, 47(1), 124-130.
[http://dx.doi.org/10.1002/jms.2034] [PMID: 22282098]
[http://dx.doi.org/10.1002/jms.2034] [PMID: 22282098]
[25]
Breindahl, T.; Petersen, K.K.; Rousing, M.L. Quantification of fentanyl in human serum by column-switching liquid chromatography and tandem mass spectrometry. J. Bioanal. Biomed., 2011, 3, 103-107.
[http://dx.doi.org/10.4172/1948-593X.1000052]
[http://dx.doi.org/10.4172/1948-593X.1000052]
[26]
Lu, L.; Li, J.; Jin, S.H.; Hu, C.Q. Combination of reversed phase liquid chromatography and zwitterion exchange-reversed phase-hydrophilic interaction mixed-mode liquid chromatography coupled with mass spectrometry for the analysis of antibiotics and their impurities. J. Chin. Pharm. Sci., 2014, 23, 106-117.
[http://dx.doi.org/10.5246/jcps.2014.02.014]
[http://dx.doi.org/10.5246/jcps.2014.02.014]
Article Metrics
12
1